Distributor inventory
Glimepiride 2 mg + Metformin hydrochloride (sustained release) 500 mg + Voglibose 0.2 mg
Type 2 diabetes mellitus in adults when blood sugar is not adequately controlled with diet, exercise and dual therapy; helps control post-meal and fasting glucose
Glimepiride (a sulfonylurea) increases insulin release from the pancreas. Metformin SR reduces glucose production in the liver and improves insulin sensitivity. Voglibose delays carbohydrate absorption in the intestine to reduce post-meal sugar spikes.
Take orally as prescribed, usually once daily with food (preferably with the first main meal). Swallow whole; do not crush or chew sustained-release tablets. Follow diet and exercise advice; monitor blood glucose regularly.
Common side effects of TRI AZULIX DS 2 may include:
Risk of hypoglycaemia (higher with missed meals, alcohol, heavy exercise); carry glucose source. Metformin may rarely cause lactic acidosis—use caution/avoid in severe kidney disease, severe liver disease, dehydration, sepsis, hypoxia; stop temporarily before/after iodinated contrast or major surgery as advised. Voglibose may cause significant gas/diarrhoea; avoid in intestinal obstruction, inflammatory bowel disease or severe digestive disorders. Monitor kidney function, liver enzymes and HbA1c; use caution in elderly.
